$115 Million

Elevation Oncology, Inc.

Initial Public Offering

Bookrunner, June 2021

Elevation Oncology, Inc.

Elevation Oncology, Inc. (“Elevation” or the “Company”) is a precision oncology company focused on developing targeted therapeutics for the treatment of cancer in genomically defined patient populations. Elevation’s lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have recently been identified as oncogenic driver alterations. The Company has designed and initiated its Phase 2 CRESTONE trial to investigate the safety and efficacy of seribantumab, an anti-HER3 monoclonal antibody, in advanced solid tumors harboring an NRG1 fusion.